1. Persistence-dependent effectiveness of tirzepatide on the cardio-metabolic-kidney syndrome outcomes in obesity : real-world evidence from the United Arab EmiratesImran Rangraze, Mohamed El-Tanani, Andrej Janež, Viviana Maggio, Syed Arman Rabbani, Mojca Jensterle Sever, Ana Munda, Elhadi Eltayeb Abbas, Humam Sami Ali, Mohammad Rashid Farooqi, Mohamed Anas Faruk Patni, Manfredi Rizzo, 2026, izvirni znanstveni članek Povzetek: Introduction: Tirzepatide has been associated with significant reductions in body weight in randomized clinical trials. However, real-world evidence evaluating the multisystemic effects of tirzepatide across the cardio-metabolic-kidney (CKM) continuum remains limited. The aim of this study was to assess the real-world persistence-driven cumulative benefits of tirzepatide beyond weight reduction in adults with obesity but without type 2 diabetes mellitus (T2DM). Methods: This single-center observational cohort study evaluated in the United Arab Emirates adults with obesity (body mass index [BMI] ≥ 30 kg/m2) treated with tirzepatide. Participants were stratified by treatment persistence: ≤ 1 year (short-term) and > 1 year (long-term). Anthropometric, glycemic, lipid, hepatic, and renal outcomes were assessed at baseline and follow-up. Results: One hundred participants (25 women; mean age 37.6 ± 10.0 years; baseline BMI 35.0 [33.0-39.0] kg/m2) were included. Median weight reduction was - 8.1% in the short-term group and - 22.6% in the long-term group (p < 0.001). 62% of long-term treated individuals achieved > 15% weight loss versus 20% among short-term users. Significant between-group differences were observed in BMI (- 8.3% vs. - 19.1%), waist circumference (- 4.0% vs. - 9.2%), and glycated hemoglobin (HbA1c) (- 5.0% vs. - 7.2%). Total cholesterol decreased by - 10.1% vs. - 18.7% (p = 0.005), low-density lipoprotein cholesterol (LDL-C) by - 9.6% vs. - 30.5% (p < 0.001), and triglycerides by - 11.2% vs. - 32.5% (p < 0.001). Liver enzymes, aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) declined by - 11.3% and - 13.2%, respectively, in long term group with no significant improvement in short term group (between-groups p values for both liver enzymes < 0.05). Serum creatinine declined significantly in the long-term group (- 6.6%, p < 0.001), estimated glomerular filtration rate (eGFR) increasing by + 3.2% (p = 0.001), and blood urea nitrogen (BUN) decreasing by - 7.8% (p = 0.006) while microalbuminuria showed no meaningful changes. Weight loss correlated with improvements in LDL-C, triglycerides, and SGOT, and inversely with high-density lipoprotein cholesterol (HDL-C) changes. Conclusions: Tirzepatide showed greater cumulative benefits across CKM syndrome outcomes during the second treatment year, highlighting the need to overcome adherence barriers in real-world settings.
Ključne besede: cardio-metabolic-kidney syndrome, obesity, tirzepatide, treatment, real-world evidence
Objavljeno v DiRROS: 12.08.2026; Ogledov: 119; Prenosov: 55
 Celotno besedilo (410,42 KB)
Gradivo ima več datotek! Več... |
2. Fine-tuning the nanostructured titanium oxide surface for selective biological responseNiharika Rawat, Metka Benčina, Domen Paul, Janez Kovač, Katja Lakota, Polona Žigon, Veronika Kralj-Iglič, Hsin-Chia Ho, Marija Vukomanović, Aleš Iglič, Ita Junkar, 2023, izvirni znanstveni članek Ključne besede: gaseous plasma treatment, hydrothermal treatment, biocompatibility, vascular stent, nanostructured surface
Objavljeno v DiRROS: 03.08.2026; Ogledov: 138; Prenosov: 119
Celotno besedilo (2,72 MB)
Gradivo ima več datotek! Več... |
3. Engineering Lactococcus cremoris strains co-expressing two cellulase genes for growth on cellulosePetra Štravs, Henri-Pierre Fierobe, Stéphanie Perret, Aleš Berlec, 2026, izvirni znanstveni članek Ključne besede: Cel5H, Cel5I, Cel9A, cancer treatment, co-expression, endoglucanases, lactic acid bacteria, cellulose, synergy
Objavljeno v DiRROS: 01.07.2026; Ogledov: 220; Prenosov: 143
Celotno besedilo (3,22 MB)
Gradivo ima več datotek! Več... |
4. Transition from parenteral to subcutaneous application of systemic oncological therapy for treating non-small-cell lung cancerAnela Muratović, Urška Janžič, 2026, izvirni znanstveni članek Povzetek: Background: The transition from the parenteral to subcutaneous application of systemic oncological therapy represents one of the most important innovations in modern oncology, as it affects the quality of life of patients as well as the organization of work and the management of health services. The introduction of this change requires effective leadership, interdisciplinary cooperation, and the adaptation of existing processes in healthcare organizations. Methods: We conducted a systematic review of the professional and scientific literature, considering the purpose and goal of this research. We used electronic databases: Wiley Online Library, PubMed, COBBIS.SI, and Google Scholar web browser. Papers from 2017 to 2025 were considered and processed using meta-synthesis. Results: Recent studies confirm that the subcutaneous administration of immunotherapy and targeted therapy is as effective and safe as parenteral immunotherapy, while significantly reducing treatment time and improving patient experience. Discussion: The transition to subcutaneous application provides an opportunity to transform oncology care. From a management perspective, the introduction of subcutaneous application requires systematic change management, staff training, process adaptation, and interdisciplinary cooperation. The sustainable implementation of innovations depends on organization, communication, and management support.
Ključne besede: lung cancer, oncological therapy, quality of medical treatment
Objavljeno v DiRROS: 30.06.2026; Ogledov: 185; Prenosov: 84
Celotno besedilo (456,65 KB) |
5. Advancing HER2-low breast cancer management : enhancing diagnosis and treatment strategiesSimona Borštnar, Ivana Bozovic-Spasojevic, Ana Cvetanović, Natalija Dedić Plavetić, Assia Konsoulova, Erika Matos, Lazar Popović, Savelina Popovska, Snjezana Tomic, Eduard Vrdoljak, 2024, izvirni znanstveni članek Povzetek: Recent evidence brought by novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates is leading to significant changes in HER2-negative breast cancer (BC) best practices. A new targetable category termed ‘HER2-low’ has been identified in tumors previously classified as ‘HER2-negative’. Daily practice in pathology and medical oncology is expected to align to current recommendations, but patient access to novel anticancer drugs across geographies might be impeded due to local challenges. Materials and methods An expert meeting involving ten regional pathology and oncology opinion leaders experienced in BC management in four Central and Eastern Europe (CEE) countries (Bulgaria, Croatia, Serbia, Slovenia) was held. Herein we summarized the current situation of HER2-low metastatic BC (mBC), local challenges, and action plans to prevent delays in patient access to testing and treatment based on expert opinion. Results Gaps and differences at multiple levels were identified across the four countries. These included variability in the local HER2-low epidemiology data, certification of pathology laboratories and quality control, and reimbursement conditions of testing and anticancer drugs for HER2-negative mBC. While clinical decisions were aligned to international guidelines in use, optimal access to testing and innovative treatment was restricted due to significant delays in reimbursement or limitative reimbursement conditions. Conclusions Preventing delays in HER2-low mBC patient access to diagnosis and novel treatments is crucial to optimize outcomes. Multidisciplinary joint efforts and pro-active discussions between clinicians and decision makers are needed to improve care of HER2-low mBC patients in CEE countries.
Ključne besede: metastatic breast cancer, HER2-low, innovative treatment
Objavljeno v DiRROS: 26.06.2026; Ogledov: 215; Prenosov: 90
Celotno besedilo (665,33 KB) |
6. Emergency and prophylactic uterine artery embolization in gynecology and obstetrics - a retrospective analysisPolona Vihtelič, Eva Skuk, Nataša Kenda Šuster, Marina Jakimovska, Peter Popović, 2024, izvirni znanstveni članek Povzetek: Background: This study aimed to evaluate the safety and efficacy of emergency and prophylactic uterine artery embolization (UAE) in our clinical practice, including technical success, clinical success, and associated complications. Patients and methods: In this retrospective study, we analyzed 64 women who underwent emergency (n =18) and prophylactic (n = 46) UAE. Indications for emergency UAE included postpartum hemorrhage or severe hemorrhage during pregnancy termination, while prophylactic UAE was performed prior to surgical removal of retained products of conception (RPOC), delivery with abnormal placental implantation, or pregnancy termination (cervical pregnancy or fetal anomalies accompanied by abnormal placental implantation). Technical success of UAE was defined as complete exclusion of the vascular lesion and contrast stasis on the final angiogram, while clinical success was defined as cessation of bleeding after UAE Termination without a hysterectomy. Results: The overall clinical success of UAE in our study was 97% (62/64). All embolization procedures were technically and clinically successful in the prophylactic group without life-threatening hemorrhages or hysterectomies (100% success rate, 46/46). However, while 100% technical success was similarly attained in the emergency group, bleeding was successfully controlled in 89% of cases (16/18). In two patients with significant blood loss (over 2000 mL), embolization failed to achieve hemostasis, resulting in persistent bleeding and subsequent hysterectomy. Conclusions: UAE is a safe and effective procedure for managing primary postpartum hemorrhage or severe hemorrhage during pregnancy termination and for decreasing the risk of severe hemorrhage during surgical removal of RPOC, delivery with abnormal placental implantation, or pregnancy.
Ključne besede: endovascular treatment, fertility, hysterectomy, postpartum hemorrhage
Objavljeno v DiRROS: 26.06.2026; Ogledov: 178; Prenosov: 148
Celotno besedilo (780,89 KB)
Gradivo ima več datotek! Več... |
7. Quantification and characterization of microplastics in seven urban wastewater treatment plantsErica Sparaventi, Rafael Nuez, María Pilar Yeste, Miguel Ángel Cauqui, Marta Sendra, 2026, izvirni znanstveni članek Povzetek: Microplastics (MPs) are routinely detected throughout wastewater treatment plants (WWTPs), yet current treatment trains were not designed specifically to remove them. This study quantified and characterized visually identified MPs in influent and effluent waters from seven urban WWTPs in Andalusia (southern Spain) during a six-month monitoring period (July–December 2020). The targeted analytical size range was 45–5000 µm, and a subset of particles was further characterized by FTIR. MPs were detected in all sampling campaigns. Concentrations ranged from 6 to 78 items/L in influent and from 12 to 65 items/L in effluent. Fibers were the dominant morphology, and the 100–500 µm size class was the most represented fraction. Among the subset analyzed by FTIR, PA, PP, PVC and LDPE were the most frequent polymer assignments, with PA predominating in the fiber-rich fraction. However, because influent and effluent 24 h time-composite samples were not hydraulic retention time (HRT)-paired and FTIR interpretation was based on a selected subset of particles, the dataset is best interpreted as describing spatiotemporal variability during the study period rather than robust process-specific removal efficiency. Overall, the results support WWTPs as an ongoing pathway for MP release to receiving environments.
Ključne besede: microplastics, wastewater treatment plants, six-month monitoring, FTIR, fibers, spatiotemporal variability
Objavljeno v DiRROS: 23.06.2026; Ogledov: 241; Prenosov: 167
Celotno besedilo (3,64 MB)
Gradivo ima več datotek! Več... |
8. Tribological performance of heat-treated Al6061 hybrid metal-matrix compositesA. D. Pradeep, K. Kannakumar, Vignesh Kumar S., S. Manojkumar, V. D. Tamilarasan, 2026, izvirni znanstveni članek Ključne besede: hybrid metal-matrix composites, heat treatment, dry-sliding wear, tungsten carbide nanoparticle
Objavljeno v DiRROS: 22.06.2026; Ogledov: 213; Prenosov: 162
Celotno besedilo (1,95 MB)
Gradivo ima več datotek! Več... |
9. |
10. Early unfractionated heparin treatment in patients with STEMI - trial design and rationaleMiša Fister, Urša Mikuž, Klemen Žiberna, Danilo Franco, Peter Radšel, Matjaž Bunc, Marko Noč, Tomaž Goslar, 2024, izvirni znanstveni članek Povzetek: The early unfractionated heparin (UFH) treatment in patients with ST-elevation myocardial infarction (STEMI) is a single-center, open-label, randomized controlled trial. The study population are patients with STEMI that undergo primary percutaneous coronary intervention (PPCI). The trial was designed to investigate whether early administration of unfractionated heparin immediately after diagnosis of STEMI is beneficial in terms of patency of infarctrelated coronary artery (IRA) when compared to established UFH administration at the time of coronary intervention. The patients will be randomized in 1:1 fashion in one of the two groups. The primary efficacy endpoint of the study is Thrombolysis in myocardial infarction (TIMI) flow grades 2 and 3 on diagnostic coronary angiography. Secondary outcome measures are: TIMI flow after PPCI, progression to cardiogenic shock, 30-day mortality, ST-segment resolution, highest Troponin I and Troponin I values at 24 hours. The safety outcome is bleeding complications. The study of early heparin administration in patients with STEMI will address whether pretreatment with UFH can increase the rate of spontaneous reperfusion of infarct-related coronary artery
Ključne besede: unfractionated heparin (UFH) treatment
Objavljeno v DiRROS: 19.06.2026; Ogledov: 239; Prenosov: 138
Celotno besedilo (658,97 KB)
Gradivo ima več datotek! Več... |
